Ownership and insider activity for Pfizer Inc. (PFE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis.
Price
| Price | $27.41 |
| Market Cap | $156.2B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-30 | BOURLA ALBERT | A-Award | 21 | |
| 2026-09-25 | Buckley Mortimer J | A-Award | 1,307 | |
| 2026-09-25 | Echevarria Joseph | A-Award | 1,613 | |
| 2026-09-25 | NARAYEN SHANTANU | A-Award | 1,743 | |
| 2026-09-25 | Quincey James | A-Award | 1,351 | |
| 2026-09-25 | SMITH JAMES C | A-Award | 1,569 | |
| 2026-09-25 | Taraporevala Cyrus | A-Award | 1,307 | |
| 2026-09-15 | BOURLA ALBERT | A-Award | 22 | |
| 2026-08-31 | BOURLA ALBERT | A-Award | 21 | |
| 2026-08-17 | Guegan Cecile |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.60B | $1.34B | $1.14B | $1.12B | $1.79B | $1.94B | $416.0M | $2.85B | $1.04B | $1.14B |
| Short-term Investments | $15.26B | $18.65B | $17.69B | $8.53B | $10.44B | $29.12B | $22.32B | $9.84B | $19.43B | $12.45B |
| Receivables | $11.27B | $11.27B | $11.40B | $9.51B | $11.18B | $15.74B | $14.53B | $15.54B | $14.78B | $15.84B |
| Inventory | $6.78B | $7.58B | $7.51B | $7.07B | $8.05B | $9.06B | $8.98B | $10.19B | $10.85B | $10.65B |
| Total Current Assets | $38.95B | $41.14B | $49.93B | $32.80B | $35.07B | $59.69B | $51.26B | $43.33B | $50.36B | $42.90B |
| Property, Plant & Equipment | $13.32B | $13.87B | $13.38B | $12.97B | $13.74B | $14.88B | $16.27B | $18.94B | $18.39B | $21.53B |
| Goodwill | $54.45B | $55.95B | $53.41B | $48.20B | $49.56B | $49.21B | $51.38B | $67.78B | $68.53B | $71.26B |
| Intangible Assets | $52.65B | $48.74B | $35.21B | $33.94B | $28.34B | $25.15B | $43.37B | $64.90B | $55.41B | $53.73B |
| Total Assets | $171.62B | $171.80B | $159.42B | $167.49B | $154.23B | $181.48B | $197.21B | $226.50B | $213.40B | $208.16B |
| Accounts Payable | $4.54B | $4.66B | $4.67B | $3.89B | $4.28B | $5.58B | $6.81B | $6.71B | $5.63B | $5.24B |
| Short-term Debt | $10.66B | $9.94B | $8.84B | $16.19B | $2.70B | $2.24B | $2.93B | $10.35B | $6.95B | $3.48B |
| Total Current Liabilities | $31.11B | $30.43B | $31.86B | $37.30B | $25.92B | $42.67B | $42.14B | $47.79B | $42.99B | $36.98B |
| Long-term Debt | $30.40B | $32.67B | $32.91B | $34.65B | $35.57B | $34.76B | $31.93B | $60.50B | $57.41B | $61.64B |
| Total Liabilities | $111.78B | $100.14B | $95.66B | $104.15B | $90.76B | $104.01B | $101.29B | $137.21B | $124.90B | $121.39B |
| Retained Earnings | $71.77B | $85.29B | $89.55B | $97.67B | $96.77B | $103.39B | $125.66B | $118.35B | $116.72B | $114.61B |
| Total Equity | $59.54B | $71.31B | $63.41B | $63.14B | $63.24B | $77.20B | $95.66B | $89.01B | $88.20B | $86.48B |
| Total Debt | $41.06B | $42.61B | $41.74B | $50.84B | $38.27B | $37.00B | $34.86B | $70.84B | $66.99B | $67.42B |
| Net Debt | $23.21B | $22.61B | $22.91B | $41.19B | $26.05B | $5.93B | $12.13B | $58.16B | $46.52B | $53.82B |
| Working Capital | $7.83B | $10.71B | $18.07B | -$4.50B | $9.15B | $17.02B | $9.12B | -$4.46B | $7.36B | $5.91B |
Financial Health
| Debt / Equity | 0.74 |
| Current Ratio | 1.27 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 2.05 |
Profitability
| Return on Equity | 8.99% |
| Return on Invested Capital | 8.84% |
| Return on Assets | 3.73% |
| Gross Margin | 71.32% |
| Operating Margin | 25.08% |
| Net Margin | 6.81% |
Related companies: AMGN · BMY · BSX · DHR · GILD · GSK · MRK
Explore sector: Healthcare · Drug Manufacturers - General
More sections of PFE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks